ADGRL4 and glioma: By treating G55 glioma–bearing mice with either anti–ELTD1 or anti–VEGFR2 antibodies, it was observed that VEGFR2 levels were decreased after anti–ELTD1 antibody treatment, and vice versa, ELTD1 levels were decreased after anti–VEGFR2 antibody treatment, compared to untreated tumors [20].